Haywood Carlton, Lanzkron Sophie, Diener-West Marie, Haythornthwaite Jennifer, Strouse John J, Bediako Shawn, Onojobi Gladys, Beach Mary Catherine
a Department of Medicine, The Johns Hopkins School of Medicine, Baltimore, MD, USA.
b Department of Biostatistics, The Johns Hopkins Bloomberg School of Public Health, Baltimore MD, USA.
Clin Trials. 2014 Jun;11(3):275-283. doi: 10.1177/1740774513519876.
Background A substantial number of planned clinical trials for sickle cell disease (SCD) have terminated early due to insufficient patient enrollment. Purpose To describe attitudes toward clinical trials among a sample of adults with SCD and identify patient-level factors associated with these attitudes. Methods Our data came from a sample (N = 291) of primarily adults with SCD participating in the Improving Patient Outcomes with Respect and Trust (IMPORT) study, which is a federally funded observational study of SCD patient experiences in seeking healthcare. Attitudes toward clinical trials were assessed using items from the Perceptions of Participation in Clinical Research instrument. Patient factors examined as potential correlates of clinical trial attitudes were demographics, disease severity, engagement in self-care, trust, healthcare experience ratings, and prior history of participation in clinical trials. Multiple regression analyses were used to identify patient-level correlates of clinical trial attitudes. Results Our sample of SCD patients expressed overwhelmingly favorable attitudes about clinical trials, with 77%-92% of our sample expressing agreement with a series of positive statements about clinical trials in general. Demographics, engagement in self-care, healthcare experience ratings, and prior trial participation each explained significant portions of the variability in clinical trial attitudes. Limitations The generalizability of our results to the entire SCD population may be of concern as the study participants were all receiving care at comprehensive sickle cell centers and already participating in clinical research. Conclusion Our results suggest that, in principle, adults with SCD enrolled in an observational study express very positive general attitudes about clinical trial participation and that specific factors attached to particular clinical trial opportunities may play a greater role in a SCD patient's decision to participate than a general unwillingness to participate.
大量针对镰状细胞病(SCD)的计划中的临床试验因患者入组不足而提前终止。
描述成年SCD患者样本对临床试验的态度,并确定与这些态度相关的患者层面因素。
我们的数据来自主要为成年SCD患者的样本(N = 291),他们参与了“以尊重和信任改善患者结局”(IMPORT)研究,这是一项由联邦资助的关于SCD患者寻求医疗保健经历的观察性研究。使用参与临床研究认知工具中的项目评估对临床试验的态度。作为临床试验态度潜在相关因素进行考察的患者因素包括人口统计学特征、疾病严重程度、自我护理参与度、信任度、医疗保健体验评分以及既往参与临床试验的历史。使用多元回归分析来确定临床试验态度的患者层面相关因素。
我们的SCD患者样本对临床试验表达了绝大多数积极的态度,77% - 92%的样本表示同意一系列关于临床试验总体的积极陈述。人口统计学特征、自我护理参与度、医疗保健体验评分以及既往参与试验情况各自解释了临床试验态度变异性的很大一部分。
由于研究参与者都在综合性镰状细胞中心接受护理且已经参与临床研究,我们的结果对整个SCD人群的可推广性可能令人担忧。
我们的结果表明,原则上,参与观察性研究的成年SCD患者对参与临床试验表达了非常积极的总体态度,并且特定临床试验机会的具体因素在SCD患者参与决策中可能比普遍不愿参与发挥更大作用。